NCT02268890View on ClinicalTrials.gov

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.

Trial Locations (6)

Unknown

Changhua

Kaohsiung City

Taichung

Tainan City

Taipei

Taoyuan District

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Taiwan Ltd

INDUSTRY